BIOREGULATOR10MG
Epithalon
Synthetic tetrapeptide (Ala-Glu-Asp-Gly). Evaluated for telomerase activity in cell-based assays.
COA Available1 vial$79.99
-10%5 vials$359.99
-20%10 vials$639.99
-25%20 vials$1199.99
For laboratory research use only. Not for human or veterinary use. Biscayne Science is not a compounding pharmacy.
Synthetic tetrapeptide (Ala-Glu-Asp-Gly). Evaluated for telomerase activity in cell-based assays.
COA Available
Synthetic tetrapeptide (Ala-Glu-Asp-Gly). Evaluated for telomerase activity in cell-based assays.
COA Available
Four-peptide blend — GHK-Cu, BPC-157, TB-500, KPV. Evaluated in fibroblast and NF-kB assays.
COA Available
Three-peptide blend — GHK-Cu, BPC-157, TB-500. Evaluated across fibroblast and endothelial assays.
COA Available
Tripeptide (Glu-Cys-Gly). Evaluated in glutathione peroxidase and reductase enzymatic assays.
COA Available
C-terminal tripeptide of alpha-MSH. Evaluated for NF-kB signaling activity in cell-based assays.
COA Available
15-residue gastric peptide fragment. Evaluated in vitro for VEGFR2-mediated cell activity.
COA Available
15-residue gastric peptide fragment. Evaluated in vitro for VEGFR2-mediated cell activity.
COA Available
Thymosin beta-4 fragment. Evaluated for actin-binding and cell-migration kinetics in vitro.
COA Available
Thymosin beta-4 fragment. Evaluated for actin-binding and cell-migration kinetics in vitro.
COA Available
Two-peptide recovery blend — BPC-157 + TB-500. Evaluated in endothelial and actin assays.
COA Available
Heptapeptide analog of tuftsin. Evaluated for BDNF expression and GABA-A modulation in vitro.
COA Available
Heptapeptide analog of ACTH(4-10). Evaluated for BDNF/TrkB signaling and NGF expression in vitro.
COA Available
Cyclic dipeptide nootropic analog. Evaluated for BDNF/NGF expression in neuronal cell assays.
COA Available
Modified GHRH(1-29) analog with Ipamorelin. Evaluated for GHRH- and GHS-receptor binding in vitro.
COA Available
Stabilized GHRH(1-44) analog. Evaluated for GHRH-receptor binding and GH-axis signaling in vitro.
COA Available
Stabilized GHRH(1-44) analog. Evaluated for GHRH-receptor binding and GH-axis signaling in vitro.
COA Available
10-residue kisspeptin fragment. Evaluated for KISS1R binding in hypothalamic cell assays.
COA Available
10-residue kisspeptin fragment. Evaluated for KISS1R binding in hypothalamic cell assays.
COA Available
Melanocortin agonist (bremelanotide), cyclic heptapeptide. Evaluated for MC4R binding in vitro.
COA Available
Copper-binding tripeptide (Gly-His-Lys). Evaluated in fibroblast collagen-expression assays.
COA Available
Copper-binding tripeptide (Gly-His-Lys). Evaluated in fibroblast collagen-expression assays.
COA Available
Cyclic alpha-MSH analog (melanotan II). Evaluated for MC1R/MC4R binding and melanogenesis in vitro.
COA Available
Nonapeptide. Evaluated for GABA-B receptor modulation in EEG-based assay models.
COA Available
Dinucleotide coenzyme. Evaluated as a cofactor in sirtuin (SIRT1-3) and PARP enzymatic assays.
COA Available
Dinucleotide coenzyme, 1000mg. Evaluated as a cofactor in sirtuin and PARP enzymatic assays.
COA Available
16-residue mitochondrial-derived peptide. Evaluated for AMPK activation in metabolic cell assays.
COA Available
Mitochondria-targeting tetrapeptide (elamipretide). Evaluated for cardiolipin binding in vitro.
COA Available
Quinolinium small molecule. Evaluated as a selective NNMT inhibitor in enzymatic and cell assays.
COA Available
Quinolinium small molecule. Evaluated as a selective NNMT inhibitor in enzymatic and cell assays.
COA Available
Lipotropic formulation with methylcobalamin (B12). Evaluated in methyl-donor and lipid assays.
COA Available
Amino-acid-derived compound. Evaluated for CPT1/CPT2 shuttle activity in beta-oxidation assays.
COA Available
Triple incretin agonist (GLP-1 / GIP / glucagon). Evaluated in receptor-binding and cAMP assays.
COA Available
Long-acting amylin receptor agonist. Evaluated for AMY/CTR binding and cAMP signaling in vitro.
COA Available